Therefore, we investigated whether NK cells can be developed as an immunotherapy against MYC-driven lymphomas by interrogating the requirement and sufficiency of NK cells in MYC-driven lymphoma initiation, and recurrence post MYC inactivation. The gene discussed is MYC; the disease is lymphoma.